D-0866-2026 Class I Ongoing
FDA drug recall D-0866-2026 was initiated by VITRUVIAS THERAPEUTICS INC on August 21, 2026 and is designated Class I. Reason for recall: Superpotent Drug The recall status is ongoing. Affected quantity: 1955 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- September 23, 2026
- Initiation Date
- August 21, 2026
- Termination Date
- N/A
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1955 bottles
Product Description
Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00.
Reason for Recall
Superpotent Drug
Distribution Pattern
US Nationwide.
Code Information
Lot # 504950, Exp Date: 09/30/2026.